📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
21 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
International journal of epidemiology · 2021
Abstract Background We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May–June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors. Methods Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). Estimates were adjusted using sampling weights and post-stratification methods. Multiple imputation was used to infer the cumulative incidence of SARS-CoV-2 infection with adjustments for imperfect tests accuracies. Results The analysis included 14 628 participants, 983 with a positive ELISA-S. The weighted estimates of seropositivity and cumulative incidence were 10.0% [95% confidence interval (CI): 9.1%, 10.9%] and 11.4% (95% CI: 10.1%, 12.8%) in IDF, 9.0% (95% CI: 7.7%, 10.2%) and 9.8% (95% CI: 8.1%, 11.8%) in GE and 3.1% (95% CI: 2.4%, 3.7%) and 2.9% (95% CI: 2.1%, 3.8%) in NA, respectively. Seropositivity was higher in younger participants [odds ratio (OR) = 1.84 (95% CI: 1.79, 6.09) in <40 vs 50–60 years old and OR = 0.56 (95% CI: 0.42, 0.74) in ≥70 vs 50–60 years old)] and when at least one child or adolescent lived in the same household [OR = 1.30 (95% CI: 1.11, 1.53)] and was lower in smokers compared with non-smokers [OR = 0.71 (95% CI: 0.57, 0.89)]. Conclusions Seropositivity to anti-SARS-CoV-2 antibodies in the French adult population was ≤10% after the first wave. Modifiable and non-modifiable risk factors were identified.
BMC infectious diseases · 2022
Abstract Background We aimed to estimate the seroprevalence of SARS-CoV-2 infection in France and to identify the populations most exposed during the first epidemic wave. Methods Random selection of individuals aged 15 years or over, from the national tax register (96% coverage). Socio-economic data, migration history, and living conditions were collected via self-computer-assisted-web or computer-assisted-telephone interviews. Home self-sampling was performed for a random subsample, to detect IgG antibodies against spike protein (Euroimmun), and neutralizing antibodies with in-house assays, in dried blood spots (DBS). Results The questionnaire was completed by 134,391 participants from May 2nd to June 2st, 2020, including 17,441 eligible for DBS 12,114 of whom were tested. ELISA-S seroprevalence was 4.5% [95% CI 3.9–5.0] overall, reaching up to 10% in the two most affected areas. High-density residences, larger household size, having reported a suspected COVID-19 case in the household, working in healthcare, being of intermediate age and non-daily tobacco smoking were independently associated with seropositivity, whereas living with children or adolescents did not remain associated after adjustment for household size. Adjustment for both residential density and household size accounted for much of the higher seroprevalence in immigrants born outside Europe, twice that in French natives in univariate analysis. Conclusion The EPICOV cohort is one of the largest national representative population-based seroprevalence surveys for COVID-19. It shows the major role of contextual living conditions in the initial spread of COVID-19 in France, during which the availability of masks and virological tests was limited.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
PloS one · 2024 · Journal Article
Champenois K, Sawras V, Ngoh P, Bouvet de la Maisonneuve P, et al.
Journal of medical virology · 2023 · Journal Article
Prétet JL, Baraquin A, Barret AS, Bercot B, et al.
PloS one · 2022 · Journal Article
Warszawski J, Meyer L, Franck JE, Rahib D, et al.
The Journal of the Association of Physicians of India · 2022 · Journal Article
Nair A, Pruthi P, L S, Marwaha V, et al.
The journal of sexual medicine · 2021 · Journal Article
Garros A, Bourrely M, Sagaon-Teyssier L, Sow A, et al.
PloS one · 2020 · Journal Article
Desai G, T S J, G SK, L M, et al.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019 · Journal Article
Ngangro NN, Velter A, Lydie N, Lot F
Cells · 2018 · Journal Article
Cécile P, Julien A, Andrea A, Agnès C, et al.
The Pan African medical journal · 2015 · Journal Article
Nlend AE, Zeudja C, Motaze AN, Suzie M, et al.
Open veterinary journal · 2025 · Journal Article
Mamadou YK, Vessaly K, Aristide ZA, Lendzele SS, et al.
BMC infectious diseases · 2022 · Journal Article
Warszawski J, Beaumont AL, Seng R, de Lamballerie X, et al.
International journal of epidemiology · 2021 · Journal Article
Carrat F, de Lamballerie X, Rahib D, Blanché H, et al.
Cureus · 2025 · Case Reports
Ghosh S, Vittobarao PG, S S, L A, et al.
Sexually transmitted infections · 2017 · Journal Article
Kersaudy-Rahib D, Lydié N, Leroy C, March L, et al.
Frontiers in pediatrics · 2023 · Journal Article
Charles MA, Ancel PY, Simeon T, Marchand-Martin L, et al.
Zhongguo gu shang = China journal of orthopaedics and traumatology · 2023 · Meta-Analysis
Zhou GB, Lyu Y, L J, Lin ZH, et al.
Archives of women's mental health · 2020 · Journal Article
El-Khoury F, Puget M, Leon C, du Roscoat E, et al.
BMJ open · 2021 · Journal Article
Bajos N, Counil E, Franck JE, Jusot F, et al.
BMC infectious diseases · 2021 · Journal Article
Carrat F, Touvier M, Severi G, Meyer L, et al.
BMC infectious diseases · 2019 · Journal Article
Brouard C, Saboni L, Gautier A, Chevaliez S, et al.
The Lancet. Public health · 2018 · Journal Article
Pannetier J, Ravalihasy A, Lydié N, Lert F, et al.
✨ Profil synthétique
IA · 24/05/2026MME Lydie BENCHAYA-CZERTOK est une rhumatologue qui a publié des travaux sur diverses pathologies et approches thérapeutiques. Ses publications sur PubMed couvrent des domaines tels que l'épidémiologie, les essais cliniques et la pédiatrie. Elle a également abordé des sujets liés à la santé mentale et à la fatigue dans ses recherches.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.